EMA Authorised: Elocta (efmoroctocog alfa) — Swedish Orphan Biovitrum AB (publ)

View source ↗

Summary

Authorisation granted for Elocta (efmoroctocog alfa) by EMA for Hemophilia A, manufacturer Swedish Orphan Biovitrum AB (publ).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Elocta (efmoroctocog alfa)

Snippet

Status: Authorised. Therapeutic area: Hemophilia A. MAH: Swedish Orphan Biovitrum AB (publ). Decision date: 15/07/2026